undamentalytics Newsletter
Sign in

Adaptive Biotechnologies Corp cash flow statement

In fiscal 2025, Adaptive Biotechnologies Corp's operations generated −$46.0m of cash; it spent $3.0m on capital projects, leaving free cash flow of −$48.9m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−35−32205−150−193−184−156−95−46−21
Depreciation and amortisation4467122120171614
Stock-based pay7111325435563545149
Capital spending261119621611433
Free cash flow−37−39194−168−254−200−167−99−49−24
Free cash flow after stock pay−44−50181−193−298−256−230−152−100−73
Shares issued——321272——————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ADPT vs VCELADPT vs VIRADPT vs ARVNADPT vs IOVA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Adaptive Biotechnologies Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Adaptive Biotechnologies Corp.